Accepting Applications for the Beacon Discovery™ Global Grant Program
Learn More

Blog

Antibodies targeting the sporozoite pGlu-CSP site can prevent malaria

Enabling Antigen-Agnostic Antibody Discovery to Identify Novel Vaccine Epitopes Against Malaria

Antibody Discovery /

Malaria is a devastating mosquito-borne disease caused by Plasmodium parasites (Pf). The Pf sporozoite represents a bottleneck in the parasite’s life cycle and is an important target for malaria interventions. The most advanced anti-sporozoite strategies to date, including the World Health Organization-approved RTS,S/AS01 and R21/MM vaccines and monoclonal antibodies (mAbs) developed as clinical products, all […]

Enabling Antigen-Agnostic Antibody Discovery to Identify Novel Vaccine Epitopes Against Malaria Read More »

Beacon Discovery™ Unveiled at AACR 2025

Announcement /

At the recent American Association for Cancer Research (AACR) 2025 Annual Meeting held in Chicago last week, Bruker Cellular Analysis proudly unveiled the Beacon Discovery™, a breakthrough benchtop platform designed to democratize live single-cell functional analysis. Buzzing with energy, the Bruker Cellular Analysis booth drew a crowd of passionate researchers, cutting-edge collaborators, and visionary innovators

Beacon Discovery™ Unveiled at AACR 2025 Read More »

Beacon Discovery™ Shines New Light on Functional Single-Cell Analysis

Antibody Discovery, Cell Therapy, T Cell Profiling /

Revolutionizing Functional Live Single-Cell Insights with the Beacon® Technology  Traditional single cell tools focus on static snapshots from one moment in a cell’s life, telling us what a cell expresses, what genes and proteins are turned on, and what surface markers are present. But they do not show how a cell behaves – they miss the

Beacon Discovery™ Shines New Light on Functional Single-Cell Analysis Read More »

Pushing the Boundaries in Cell Line Development: Webinar Recap

Cell Line Development /

This past February and March, Bruker Cellular Analysis, in partnership with BioProcess International, hosted a dynamic two-part webinar series – Pushing the Boundaries in Cell Line Development – spotlighting the capabilities of the Beacon® Optofluidic platform for cell line development (CLD). Now available on demand, these sessions offer a front-row view into how cutting-edge technology

Pushing the Boundaries in Cell Line Development: Webinar Recap Read More »

Efficiently Generating and Selecting Broadly Neutralizing Antibodies with Mosaic Nanoparticle Immunization and Multiplexed Screening

Antibody Discovery /

Therapeutic monoclonal antibodies (mAbs) have become less effective against SARS-CoV-2 infections as new variants arise due to point mutations in the spike protein that reduce antibody binding. To induce production of broadly neutralizing antibodies that target a conserved receptor-binding domain (RBD) region, protecting against multiple SARS-CoV-2 variants and zoonotic sarbecoviruses, researchers at the California Institute

Efficiently Generating and Selecting Broadly Neutralizing Antibodies with Mosaic Nanoparticle Immunization and Multiplexed Screening Read More »

AI Needs More Than Sequences to Cure Cancer – It Needs Sequence Data Linked to Functional Outcomes

Cancer Immunology, Cancer Signaling, Oncology /

“If you want to advance human health and you’re not working towards AGI [Artificial General Intelligence]/ASI [Artificial Super Intelligence] right now the 2 most important things you can be building are enabling hardware and/or scientific data sets/reliable biological data that no one else can or will create. All the ‘AGI will solve cancer’ claims are

AI Needs More Than Sequences to Cure Cancer – It Needs Sequence Data Linked to Functional Outcomes Read More »

Recent Advancements in Therapeutic Antibody Discovery: Bispecific Antibodies, ADCs, Fully Human Antibodies, and Technology Driving Antibody Discovery Forward

Antibody Discovery /

Therapeutic antibodies are transforming medicine, offering precision treatments for cancer, autoimmune diseases, and infections. Recent advancements in antibody discovery and engineering have accelerated the pace of therapeutic development, focusing on approaches such as bispecific antibodies, antibody-drug conjugates (ADCs), and fully humanized antibodies. This blog dives into recent trends and how platforms like the Beacon optofluidic

Recent Advancements in Therapeutic Antibody Discovery: Bispecific Antibodies, ADCs, Fully Human Antibodies, and Technology Driving Antibody Discovery Forward Read More »

Revolutionizing Bispecific Antibody Production Using the Beacon® Platform

Cell Line Development /

Bispecific Antibodies: An Emerging Therapeutic Paradigm Bispecific antibodies (bsAbs) are rapidly gaining momentum in the pharmaceutical industry as a revolutionary class of therapeutics. While monoclonal antibodies (mAbs) have dominated the biologics landscape for decades, bsAbs offer unique therapeutic mechanisms by targeting two different antigens simultaneously. This capability enables novel treatment strategies, particularly in cancer immunotherapy,

Revolutionizing Bispecific Antibody Production Using the Beacon® Platform Read More »